Conclusion
glioblastoma, tumor, Tumor
RECURRENCES, TUMOR, TUMOR, ADVERSE EVENTS, REGRESSION, GLIOBLASTOMA
Prolonged intraparenchymal infusion of the pro-differentiation cytokine hrBMP4, targeting GSCs, was safe and without drug-related severe adverse events in glioblastoma recurrences. Three patients exhibited durable tumor response, two of which showed sustained, complete regression of the treated tumor and extended survival. Tumor growth was greatly reduced in areas permeated by hrBMP4. This supports the implementation of Phase 2 trials powered to validate the efficacy of this pro-differentiation treatment in glioblastoma.